Results 61 to 70 of about 2,787,964 (309)
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu +9 more
wiley +1 more source
EPI Update, September 2, 2011 [PDF]
, 2011 Weekly newsletter for Center For Acute Disease Epidemiology of Iowa Department of Public ...
core
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To compare the effectiveness and safety of tenecteplase (TNK) versus alteplase (TPA) in patients with basilar artery occlusion prior to endovascular treatment (EVT). Methods In this retrospective multicenter study (BAO‐TNK), we analyzed consecutive BAO patients from 14 U.S.
Rahul R. Karamchandani +38 more
wiley +1 more source
EPI Update, May 18, 2010 [PDF]
, 2010 Weekly newsletter for Center For Acute Disease Epidemiology of Iowa Department of Public ...
core
Insights from unifying modern approximations to infections on networks [PDF]
, 2010 Networks are increasingly central to modern science owing to their ability to conceptualize multiple interacting components of a complex system.
Anderson R. M. +4 more
core +2 more sources
Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin +2 more
wiley +1 more source
EPI Update, September 11, 2009 [PDF]
, 2009 Weekly newsletter for Center For Acute Disease Epidemiology of Iowa Department of Public ...
core
Molecular epidemiology of African sleeping sickness [PDF]
, 2009 Human sleeping sickness in Africa, caused by Trypanosoma brucei spp. raises a number of questions. Despite the widespread distribution of the tsetse vectors and animal trypanosomiasis, human disease is only found in discrete foci which periodically give ...
A. TAIT +5 more
core +2 more sources
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer +14 more
wiley +1 more source
EPI Update, June 3, 2011 [PDF]
, 2011 Weekly newsletter for Center For Acute Disease Epidemiology of Iowa Department of Public ...
core